Summary
Schering-Plough Corporation reported a significant increase in net sales for the three and six months ended June 30, 2008, primarily driven by the acquisition of Organon BioSciences N.V. (OBS) in November 2007. However, net income available to common shareholders decreased year-over-year for both periods, largely due to higher costs associated with the OBS integration, increased interest expense from new debt, and purchase accounting adjustments. The company is undertaking a "Productivity Transformation Program" (PTP) to streamline operations and achieve cost savings. The company's cholesterol franchise, VYTORIN and ZETIA, managed through a joint venture with Merck, experienced declining sales in the U.S. market, attributed to media scrutiny following the ENHANCE clinical trial results. This trend, along with ongoing investigations and litigation related to the trial, poses a significant risk to future performance. The company remains committed to defending its position and cooperating with investigations. Investors should closely monitor the impact of the OBS integration and the challenges facing the cholesterol franchise.
Financial Highlights
22 data pointsKey Highlights
- 1Net sales increased by 55% to $4.9 billion for the three months ended June 30, 2008, and by 56% to $9.6 billion for the six months ended June 30, 2008, primarily due to the acquisition of Organon BioSciences N.V. (OBS).
- 2Net income available to common shareholders decreased to $398 million for the three months and $651 million for the six months ended June 30, 2008, compared to $517 million and $1.1 billion respectively in the prior year periods.
- 3The "Productivity Transformation Program" (PTP) was launched to achieve $1.5 billion in annualized savings by 2012, including integration costs from OBS and other efficiency measures.
- 4Sales of the cholesterol franchise (VYTORIN and ZETIA) in the U.S. declined by 16% for the six months ended June 30, 2008, due to negative media attention and scrutiny surrounding the ENHANCE clinical trial results.
- 5The company is facing significant governmental inquiries, investigations, and litigation related to the ENHANCE clinical trial, its disclosures, and stock sales by officers, which could have a material adverse effect on financial condition.
- 6Research and development expenses increased by 30% for the quarter and 27% for the six months, reflecting continued investment in pipeline development and integration of OBS's R&D capabilities.
- 7The company reported $1.38 billion in cash flow from operating activities for the first six months of 2008, a significant increase from $628 million in the prior year, partly due to the absence of acquisition-related payments seen in 2007.